Last reviewed · How we verify
PF-07259955 (pf-07259955)
At a glance
| Generic name | pf-07259955 |
|---|---|
| Sponsor | Pfizer Inc. |
| Phase | Phase 1 |
Approved indications
Common side effects
- Application site erythema
- Application site irritation
- Application site pruritus
- Application site pain
- Application site papules
- Scratch
- Skin abrasion
- Application site dryness
- Fatigue
- Contusion
- Blood potassium increased
- Liver function test increased
Key clinical trials
- A First-in-human Study of Multiple Doses of Topically Administered PF-07295324 and PF-07259955 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |